Abstract

The advent of microarray technology has enabled scientists to simultaneously investigate the expression of thousands of genes. Gene-expression profiling studies have provided a molecular classification of breast cancer into clinically relevant subtypes, new tools to predict disease recurrence and response to different treatments, and new insights into various oncogenic pathways and the process of metastatic progression. Here we describe the state of the art of gene-expression studies in breast cancer, and consider both their current limitations and future promises. We also discuss the potential of molecular signatures to have an impact on individual breast cancer patient management, and ultimately to accelerate the transition between empirical and tailored medicine.

Author affiliations

1. Christos Sotiriou is at the Translational Research Unit, Jules Bordet Institute, 121 Boulevard de Waterloo, 1000 Brussels, Belgium.
2. Martine J. Piccart is at the Medicine Department, Jules Bordet Institute, 121 Blvd de Waterloo, 1000 Brussels, Belgium.

Correspondence to: Martine J. Piccart² Email: martine.piccart@bordet.be

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.